264 related articles for article (PubMed ID: 36829176)
1. Integrated multi-omics analyses and functional validation reveal TTK as a novel EMT activator for endometrial cancer.
Miao Y; Konno Y; Wang B; Zhu L; Zhai T; Ihira K; Kobayashi N; Watari H; Jin X; Yue J; Dong P; Fang M
J Transl Med; 2023 Feb; 21(1):151. PubMed ID: 36829176
[TBL] [Abstract][Full Text] [Related]
2. TTK, CDC25A, and ESPL1 as Prognostic Biomarkers for Endometrial Cancer.
Yang Q; Yu B; Sun J
Biomed Res Int; 2020; 2020():4625123. PubMed ID: 33282948
[TBL] [Abstract][Full Text] [Related]
3. CWH43 Is a Novel Tumor Suppressor Gene with Negative Regulation of TTK in Colorectal Cancer.
Lee CC; Tsai KY; Lee AW; Wei PL; Huang CY; Batzorig U; Chang YJ
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894942
[TBL] [Abstract][Full Text] [Related]
4. TTK (threonine tyrosine kinase) regulates the malignant behaviors of cancer cells and is regulated by microRNA-582-5p in ovarian cancer.
Lu N; Ren L
Bioengineered; 2021 Dec; 12(1):5759-5768. PubMed ID: 34516342
[TBL] [Abstract][Full Text] [Related]
5. MiR-29a-5p inhibits proliferation and invasion and induces apoptosis in endometrial carcinoma via targeting TPX2.
Jiang T; Sui D; You D; Yao S; Zhang L; Wang Y; Zhao J; Zhang Y
Cell Cycle; 2018; 17(10):1268-1278. PubMed ID: 29888640
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-183 induces epithelial-mesenchymal transition and promotes endometrial cancer cell migration and invasion in by targeting CPEB1.
Xiong H; Chen R; Liu S; Lin Q; Chen H; Jiang Q
J Cell Biochem; 2018 Nov; 119(10):8123-8137. PubMed ID: 29923214
[TBL] [Abstract][Full Text] [Related]
7. MiR-195 inhibits migration, invasion and epithelial-mesenchymal transition (EMT) of endometrial carcinoma cells by targeting SOX4.
Zhao X; Dai L; Yue Q; Wang H; Wang XU; Li Y; Chen R
J Biosci; 2019 Dec; 44(6):. PubMed ID: 31894127
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1.
Dong P; Kaneuchi M; Watari H; Hamada J; Sudo S; Ju J; Sakuragi N
Mol Cancer; 2011 Aug; 10():99. PubMed ID: 21851624
[TBL] [Abstract][Full Text] [Related]
9. HLF/miR-132/TTK axis regulates cell proliferation, metastasis and radiosensitivity of glioma cells.
Chen S; Wang Y; Ni C; Meng G; Sheng X
Biomed Pharmacother; 2016 Oct; 83():898-904. PubMed ID: 27522003
[TBL] [Abstract][Full Text] [Related]
10. Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression.
Dong P; Ihira K; Xiong Y; Watari H; Hanley SJ; Yamada T; Hosaka M; Kudo M; Yue J; Sakuragi N
Oncotarget; 2016 Apr; 7(15):20260-70. PubMed ID: 26934121
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of
Tsai YM; Wu KL; Chang YY; Hung JY; Chang WA; Chang CY; Jian SF; Tsai PH; Huang YC; Chong IW; Hsu YL
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121246
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA VPS9D1-AS1 enhances proliferation, invasion, and epithelial-mesenchymal transition in endometrial cancer via miR-377-3p/SGK1.
Peng TF; Zhou YJ; Zhou J; Zhou Y; Li XC; Ouyang Q
Kaohsiung J Med Sci; 2022 Nov; 38(11):1048-1059. PubMed ID: 36245426
[TBL] [Abstract][Full Text] [Related]
13. miR-326 regulates EMT and metastasis of endometrial cancer through targeting TWIST1.
Liu W; Zhang B; Xu N; Wang MJ; Liu Q
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(17):3787-3793. PubMed ID: 28975990
[TBL] [Abstract][Full Text] [Related]
14. Silencing TTK expression inhibits the proliferation and progression of prostate cancer.
Chen S; Wang J; Wang L; Peng H; Xiao L; Li C; Lin D; Yang K
Exp Cell Res; 2019 Dec; 385(1):111669. PubMed ID: 31605696
[TBL] [Abstract][Full Text] [Related]
15. An EMT-related genes signature as a prognostic biomarker for patients with endometrial cancer.
Yu Y; Zhang Y; Li Z; Dong Y; Huang H; Yang B; Zhao E; Chen Y; Yang L; Lu J; Qiu F
BMC Cancer; 2023 Sep; 23(1):879. PubMed ID: 37723477
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of TTK expression is associated with poor prognosis and immune infiltration in endometrial cancer patients.
Du H; Zhang L; Chen J; Chen X; Qiang R; Ding X; Wang Y; Yang X
Cancer Cell Int; 2024 Jan; 24(1):20. PubMed ID: 38195567
[TBL] [Abstract][Full Text] [Related]
17. BUB1, BUB1B, CCNA2, and CDCA8, along with miR-524-5p, as clinically relevant biomarkers for the diagnosis and treatment of endometrial carcinoma.
Hao Q; Wu H; Liu E; Wang L
BMC Cancer; 2023 Oct; 23(1):995. PubMed ID: 37853361
[TBL] [Abstract][Full Text] [Related]
18. FOXM1 Contributes to Chemotherapy Sensitivity in Cervical Cancer by Regulating TTK.
Tang Q; Xu A; Yang Y; Zhang Y; Sun J
Discov Med; 2023 Jun; 35(176):208-220. PubMed ID: 37272088
[TBL] [Abstract][Full Text] [Related]
19. TTK is a potential regulator of tumor progression correlated with dedifferentiation and immune cell infiltration in papillary thyroid cancer.
Ma JJ; Xiang C; Wang JW
Aging (Albany NY); 2023 Oct; 15(19):10607-10626. PubMed ID: 37815894
[TBL] [Abstract][Full Text] [Related]
20. High tyrosine threonine kinase expression predicts a poor prognosis: a potential therapeutic target for endometrial carcinoma.
Cui CH; Wu Q; Zhou HM; He H; Wang Y; Tang Z; Zhang Y; Wang X; Xiao J; Zhang H
Ann Transl Med; 2022 Dec; 10(24):1352. PubMed ID: 36660721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
